01.002 RWE GS Aug 2022 C 12-8-22

Real-world evidence supports CAR-T-cell therapy’s safety and efficacy

  • A retrospective study in 275 (treated) patients with relapsed or refractory large B-cell lymphoma found (Yescarta) axicabtagene ciloleucel gave similar responses to those seen in clinical trials
  • This evidence is valuable in supporting the clinical trial results; because “The issue with clinical trials is that they often are very highly selective,” – Michael D. Jain, MD, PhD; Moffitt Cancer Center
  • “Our work is important because it shows that even those patients who don’t strictly adhere to clinical trial inclusion and exclusion criteria can still benefit from this therapy,” – Michael D. Jain
  • These real-world results should give clinicians confidence with prescribing the CAR-T, especially for patients who do not fall under the clinical trial criteria
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at